A carregar...
Publicação
c-Met expression in renal cell carcinoma with bone metastases
Orientador(es)
Resumo(s)
Hepatocyte growth factor (HGF)/c-Met pathway is implicated in embryogenesis and organ development and differentiation. Germline or somatic mutations, chromosomal rearrangements, gene amplification, and transcriptional upregulation in MET or alterations in autocrine or paracrine c-Met signalling have been associated with cancer cell proliferation and survival, including in renal cell carcinoma (RCC), and associated with disease progression. HGF/c-Met pathway has been shown to be particularly relevant in tumors with bone metastases (BMs). However, the efficacy of targeting c-Met in bone metastatic disease, including in RCC, has not been proven. Therefore, further investigation is required focusing the particular role of HGF/c-Met pathway in bone microenvironment (BME) and how to effectively target this pathway in the context of bone metastatic disease.
Descrição
© 2020 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/BY-NC-ND/4.0/)
Palavras-chave
Bone metastases Kidney cancer HGF/c-Met Targeted therapy
Contexto Educativo
Citação
J Bone Oncol. 2020 Sep 16;25:100315.
Editora
Elsevier